Cognitive Disorder and Brain Aging – CDBA
*Starts with January 2025 council round submission deadline
The Cognitive Disorders and Brain Aging (CDBA) study section reviews applications studying primary and secondary cognitive disorders of aging (age 65 and above) focusing on functional manifestations of cognitive deficits measured by behavioral evaluations and neuroimaging approaches in human subjects and vertebrate animals. The scope of topics include etiology, diagnosis, symptom progression, and intervention of cognitive impairments in normal aging and age-related neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), and Vascular cognitive impairment and dementia (VCID). Clinical and preclinical studies using laboratory-based, experimental, and observational approaches to examine the cognitive sequelae of brain aging and degeneration are reviewed in this study section.
Review Dates
Topics
- Biological factors conferring vulnerability or resilience to cognitive decline.
- Biological, genetic, and neural factors underlying aging disorders with emphasis on the relationship between these factors and clinical or functional behavioral profile over time.
- Effects of age-related factors and their treatments on cognitive function.
- Delirium, mild cognitive impairment, and dementia when the emphasis is on the effects of age-related neurodegeneration in vertebrate animals.
- Research addressing identification of methods for treatment and/or rehabilitation of aging-associated cognitive disorders including but not limited to pharmacological, biological, electrophysiological, brain stimulation, or other means to slow down or reverse cognitive impairments.
- Neuropsychiatric symptoms such as agitation, aggression, delusions, depression, apathy, disinhibition, etc. in combination with cognitive impairment in neurodegeneration
- Neuroimaging studies of cognition and behavioral states in cognitive aging and neuroimaging studies of neurodegeneration in vertebrate animals.
- Studies including large scale data related to cognitive outcomes across the lifespan.
- Genomic and epigenetic studies relating to cognitive risk as a function of the aging brain.
Shared Interests and Overlaps
There are shared interests in cognitive aging and disorders with Aging Systems and Geriatrics Study Section (ASG). Applications that emphasize behavioral and cognitive aspects of aging and the associated degenerative disorders are reviewed in CDBA in addition to applications that address delirium in vertebrate animals. Applications that emphasize mechanistic studies on aging-related brain degenerations in the context of geoscience in humans are reviewed in ASG.
There are shared interests in cognitive dysfunctions in neurodegenerative disorders with Chronic Dysfunction and Integrative Neurodegeneration Study Section (CDIN). Applications that emphasize animal studies on delirium and cognitive behavioral outcomes in humans are reviewed in CDBA. Applications that emphasize preclinical studies on neurodegenerative disorders are reviewed in CDIN.
There are shared interests in cognitive impairment in aging-associated neurodegeneration with Clinical Neurodegeneration Translational Neuroscience (CNTN). Applications that emphasize behavioral and cognitive aspects/outcomes in aging and aging-related disorders are reviewed in CDBA. Applications that emphasize clinical brain pathology, circuit structures and functions, biomarkers, diagnosis, progression, and treatment of neurodegenerative disorders are reviewed in CNTN.
There are shared interests in aging and associated neurodegenerative disorders with Adult Lifespan Psychopathology Study Section (ALP). Applications that focus on psychopathology emerging later in life, including forms secondary to neurological or neurodegenerative disorders are reviewed in ALP. Applications dealing with neuropsychiatric symptoms of neurodegenerative disorders that combine with cognitive impairment are reviewed in CDBA, whereas those that emphasize psychiatric symptoms are reviewed in ALP.
There are shared interests in human cognition with Human Complex Mental Function (HCMF). Applications that emphasize age-related cognitive changes in older adults (age 65 or above) and risk for dementia or other neurodegenerative disorders and premorbid conditions are reviewed in CDBA. Applications that emphasize normative cognitive change/decline are reviewed in HCMF.
There are shared interests in neurological conditions related to aging with Neurological, Mental and Behavioral Health (NMBH). Applications that emphasize cognitive and behavioral outcomes in aging-associated neurodegeneration are reviewed in CDBA. Applications that emphasize population health perspectives and data analysis of large populations in health consequences are reviewed in NMBH.
There are shared interests in genetic, genomic and epigenetic factors contributing to the risk factor and/or physiopathology of neurodegenerative disorders with Molecular Neurogenetics Study Section (MNG). Applications that emphasize genetic factors correlating with cognitive and behavioral outcomes in aging and neurodegeneration are reviewed in CDBA. Applications that emphasize the development of genetic approaches and or on hypothesis driven mechanistic studies in aging and neurodegeneration are reviewed in MNG.
There are shared interests in sleep disorders and eating disorders with Neural Basis of Psychopathology, Addictions, and Sleep Disorders (NPAS). Applications that emphasize cognitive disorders during aging in adults are reviewed in CDBA. Applications that emphasize the etiology, neural mechanisms, diagnosis, and treatment of sleep disorders in humans are reviewed in NPAS.
